Entrada Therapeutics announced that an independent Data Monitoring Committee has recommended increasing the dose to 10 mg/kg for Cohort 2 in its ELEVATE-45-201 Phase 1/2 trial for Duchenne muscular dystrophy. This follows safety and pharmacokinetic reviews of Cohort 1 participants dosed at 5 mg/kg. The trial evaluates ENTR-601-45, targeting patients amenable to exon 45 skipping, with dosing every six weeks. Entrada plans to report Cohort 1 data mid-2026, with subsequent data from higher doses to follow, aiming to improve patient outcomes and reduce treatment burden.
Pepeto's presale rapidly exceeded $10.41 million, attracting large XRP holders who see limited upside in XRP's predicted $6 price despite ongoing political hurdles. Pepeto's unique model, led by a former Binance executive, integrates token demand dir...
Pomerantz LLP is investigating Oxford Industries and some of its executives for potential securities fraud following the company's significant reduction in its 2026 revenue guidance and lower-than-expected Q2 sales projections. This announcement caus...
Enerpac Tool Group announced it will acquire Specialized Fabrication Equipment Group (SFE Group) for approximately $472 million in cash. The acquisition adds a portfolio of 12 premium industrial tool brands and expands Enerpac’s presence in higher-gr...
Pomerantz LLP is investigating ON Semiconductor Corporation for potential securities fraud following its announcement to acquire Synaptics Incorporated in an all-stock deal valued at around $7 billion. The deal offers Synaptics shareholders 1.35 ON S...
Nasdaq announced that Pitanium Limited's securities will be delisted from the Nasdaq Stock Market on July 16, 2026, unless the company appeals the decision. Trading of Pitanium shares has been halted since October 18, 2025, following a suspension by ...
